EVENTS
BOSTON, MA – Jun 17 – Jun 20, 2019

Invivoscribe to Present at The Inaugural World Pharma Week

EVENTS
BOSTON, MA – Jun 17 – Jun 20, 2019

Invivoscribe to Present at The Inaugural World Pharma Week

The World Pharma Week brings together four congresses: 15th Annual Biomarker World Congress, 18th Annual World Preclinical Congress, Inaugural IO Pharma Congress, and the Inaugural Digital Health Pharma Congress. More than 1,500 professionals representing top pharmaceutical companies and universities come together to discuss and share cutting-edge technologies in the drug discovery space.

In the Immuno-Oncology Biomarkers 1: Predictive Biomarkers and Companion Diagnostics track, our Head of Global Business Development, Dr. Michael Vishnevetsky, will present Invivoscribe’s Streamlined CDxTM program. Companion diagnostics have played a pivotal role in defining the efficacy of targeted therapies. The Streamlined CDxTM partnership model, deployed in the first-ever AML companion diagnostic: the LeukoStrat® CDx FLT3 Mutation Assay, has been shown to collapse development timelines, and improve selection of patient cohorts, leading to earlier submissions and accelerated approvals of new targeted therapies.

Presentation information:

Date: Tuesday, June 18th, 2019
Time: 11:25 am EST
Track: Immuno-Oncology Biomarkers 1: Predictive Biomarkers and Companion Diagnostics
Venue: Seaport World Trade Center

Come visit us at Booth 223! Michael Vishnevetsky will also be available to meet in one-on-one meetings with registered attendees to further discuss partnership opportunities. To arrange a meeting, please contact us at cdx@invivoscribe.com. You may also contact Invivoscribe at support@invivoscribe.com.

The World Pharma Week brings together four congresses: 15th Annual Biomarker World Congress, 18th Annual World Preclinical Congress, Inaugural IO Pharma Congress, and the Inaugural Digital Health Pharma Congress. More than 1,500 professionals representing top pharmaceutical companies and universities come together to discuss and share cutting-edge technologies in the drug discovery space.

In the Immuno-Oncology Biomarkers 1: Predictive Biomarkers and Companion Diagnostics track, our Head of Global Business Development, Dr. Michael Vishnevetsky, will present Invivoscribe’s Streamlined CDxTM program. Companion diagnostics have played a pivotal role in defining the efficacy of targeted therapies. The Streamlined CDxTM partnership model, deployed in the first-ever AML companion diagnostic: the LeukoStrat® CDx FLT3 Mutation Assay, has been shown to collapse development timelines, and improve selection of patient cohorts, leading to earlier submissions and accelerated approvals of new targeted therapies.

Presentation information:

Date: Tuesday, June 18th, 2019
Time: 11:25 am EST
Track: Immuno-Oncology Biomarkers 1: Predictive Biomarkers and Companion Diagnostics
Venue: Seaport World Trade Center

Come visit us at Booth 223! Michael Vishnevetsky will also be available to meet in one-on-one meetings with registered attendees to further discuss partnership opportunities. To arrange a meeting, please contact us at cdx@invivoscribe.com. You may also contact Invivoscribe at support@invivoscribe.com.

SHARE THIS EVENT
UPCOMING

Invivoscribe Events

UPCOMING

Invivoscribe Events

2019-07-11T05:22:32+00:00